09 Sep Scarab Genomics and NeoClone enter into license agreement
Scarab Genomics, a leader in E coli technology, has entered into a license agreement with NeoClone to market and distribute their proprietary antibodies against Shiga toxin. According to Frederick R. Blattner, PhD, founder and President of Scarab Genomics, the research and diagnostic markets will welcome access to these high quality reagents.
Shiga toxin is secreted by E. coli bacteria, which can cause disease or even death when consumed, most often in undercooked hamburgers. The study of it is important because at present time there is no treatment; antibiotics actually cause an increase in the toxin and just make things worse. While the specifics of the agreement were not disclosed, both companies have indicated that the cost in developing the antibodies and the revenues will be shared.
“Given Scarab’s deep expertise in this area, NeoClone is very excited to have them as a commercial partner” stated Deven McGlenn, NeoClone’s CEO. Both Scarab Genomics and NeoClone are based in Madison, WI.